We Think Relay Therapeutics (NASDAQ:RLAY) Needs To Drive Business Growth Carefully

Simply Wall StDec 19 23:58

Relay Therapeutics Insider Sold Shares Worth $500,000, According to a Recent SEC Filing

MT NewswiresDec 19 05:58

JMP Securities Reiterates Market Outperform on Relay Therapeutics, Maintains $21 Price Target

BenzingaDec 12 22:28 · Ratings

Relay Therapeutics Analyst Ratings

BenzingaDec 12 22:25 · Ratings

TD Cowen Maintains Relay Therapeutics(RLAY.US) With Buy Rating

Futu NewsDec 12 21:31 · Ratings

Jefferies Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $17

Futu NewsDec 12 21:31 · Ratings